Role of histone acetylation in the stimulatory effect of valproic acid on vascular endothelial tissue-type plasminogen activator expression

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Larsson, Pia ^a   Ulfhammer, Erik ^a   Magnusson, Mia ^a   Bergh, Niklas ^a   Lunke, Sebastian ^b   El Osta, Assam ^b   Medcalf, Robert L ^c   Svensson, Per Arne ^d   Karlsson, Lena ^a   Jern, Sverker ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 7; HISTONE H3; HISTONE H4; SMALL INTERFERING RNA; TISSUE PLASMINOGEN ACTIVATOR; VALPROIC ACID; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; ENDOTHELIUM CELL; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SECRETION; TRANSCRIPTION INITIATION SITE; WESTERN BLOTTING; ACETYLATION; CORONARY BLOOD VESSEL; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HEMOSTASIS; METABOLISM; SECRETION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM;

ACETYLATION; CHROMATIN IMMUNOPRECIPITATION; CORONARY VESSELS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HEMOSTASIS; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; RNA, SMALL INTERFERING; TISSUE PLASMINOGEN ACTIVATOR; VALPROIC ACID;

EID: 84857437046     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031573     Document Type: Article

References (37)

1. Kathiresan S, Yang Q, Larson MG, Camargo AL, Tofler GH, et al. (2006) Common genetic variation in five thrombosis genes and relations to plasma hemostatic protein level and cardiovascular disease risk. Arterioscler Thromb Vasc Biol 26: 1405-1412.
2. Ladenvall P, Johansson L, Jansson JH, Jern S, Nilsson TK, et al. (2002) Tissue-type plasminogen activator -7,351C/T enhancer polymorphism is associated with a first myocardial infarction. Thromb Haemost 87: 105-109.
3. Hrafnkelsdottir T, Ottosson P, Gudnason T, Samuelsson O, Jern S, (2004) Impaired endothelial release of tissue-type plasminogen activator in patients with chronic kidney disease and hypertension. Hypertension 44: 300-304.
4. Hrafnkelsdottir T, Wall U, Jern C, Jern S, (1998) Impaired capacity for endogenous fibrinolysis in essential hypertension. Lancet 352: 1597-1598.
5. Ridderstrale W, Ulfhammer E, Jern S, Hrafnkelsdottir T, (2006) Impaired capacity for stimulated fibrinolysis in primary hypertension is restored by antihypertensive therapy. Hypertension 47: 686-691.
6. Van Guilder GP, Hoetzer GL, Smith DT, Irmiger HM, Greiner JJ, et al. (2005) Endothelial t-PA release is impaired in overweight and obese adults but can be improved with regular aerobic exercise. Am J Physiol Endocrinol Metab 289: E807-813.
7. Osterlund B, Jern S, Jern C, Seeman-Lodding H, Ostman M, et al. (2008) Impaired myocardial t-PA release in patients with coronary artery disease. Acta Anaesthesiol Scand 52: 1375-1384.
8. Newby DE, McLeod AL, Uren NG, Flint L, Ludlam CA, et al. (2001) Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation 103: 1936-1941.
9. Arts J, Lansink M, Grimbergen J, Toet KH, Kooistra T, (1995) Stimulation of tissue-type plasminogen activator gene expression by sodium butyrate and trichostatin A in human endothelial cells involves histone acetylation. Biochem J 310 (Pt 1): 171-176.
10. Kooistra T, van den Berg J, Tons A, Platenburg G, Rijken DC, et al. (1987) Butyrate stimulates tissue-type plasminogen-activator synthesis in cultured human endothelial cells. Biochem J 247: 605-612.
11. Dunoyer-Geindre S, Kruithof EK, (2011) Epigenetic control of tissue-type plasminogen activator synthesis in human endothelial cells. Cardiovasc Res 90: 457-463.
12. Shahbazian MD, Grunstein M, (2007) Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 76: 75-100.
13. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978.
14. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, et al. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741.
15. Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, et al. (2004) Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 65: 520-527.
16. Jaffe EA, Nachman RL, Becker CG, Minick CR, (1973) Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52: 2745-2756.
17. Muldowney JA 3rd, Painter CA, Sanders-Bush E, Brown NJ, Vaughan DE, (2007) Acute tissue-type plasminogen activator release in human microvascular endothelial cells: the roles of Galphaq, PLC-beta, IP3 and 5,6-epoxyeicosatrienoic acid. Thromb Haemost 97: 263-271.
18. Henderson BR, Sleigh MJ, (1992) TATA box-independent transcription of the human tissue plasminogen activator gene initiates within a sequence conserved in related genes. FEBS Lett 309: 130-134.
19. Harikrishnan KN, Karagiannis TC, Chow MZ, El-Osta A, (2008) Effect of valproic acid on radiation-induced DNA damage in euchromatic and heterochromatic compartments. Cell Cycle 7: 468-476.
20. Strahl BD, Allis CD, (2000) The language of covalent histone modifications. Nature 403: 41-45.
21. Shogren-Knaak M, Ishii H, Sun JM, Pazin MJ, Davie JR, et al. (2006) Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 311: 844-847.
22. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS, (2004) Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64: 1079-1086.
23. Rossig L, Li H, Fisslthaler B, Urbich C, Fleming I, et al. (2002) Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ Res 91: 837-844.
24. Mariadason JM, Corner GA, Augenlicht LH, (2000) Genetic reprogramming in pathways of colonic cell maturation induced by short chain fatty acids: comparison with trichostatin A, sulindac, and curcumin and implications for chemoprevention of colon cancer. Cancer Res 60: 4561-4572.
25. Van Lint C, Emiliani S, Verdin E, (1996) The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 5: 245-253.
26. Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, et al. (1997) Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 241: 142-150.
27. Kim S, Kang JK, Kim YK, Seo DW, Ahn SH, et al. (2006) Histone deacetylase inhibitor apicidin induces cyclin E expression through Sp1 sites. Biochem Biophys Res Commun 342: 1168-1173.
28. Zhang Y, Dufau ML, (2002) Silencing of transcription of the human luteinizing hormone receptor gene by histone deacetylase-mSin3A complex. J Biol Chem 277: 33431-33438.
29. Takakura M, Kyo S, Sowa Y, Wang Z, Yatabe N, et al. (2001) Telomerase activation by histone deacetylase inhibitor in normal cells. Nucleic Acids Res 29: 3006-3011.
30. Arts J, Herr I, Lansink M, Angel P, Kooistra T, (1997) Cell-type specific DNA-protein interactions at the tissue-type plasminogen activator promoter in human endothelial and HeLa cells in vivo and in vitro. Nucleic Acids Res 25: 311-317.
31. Medcalf RL, Ruegg M, Schleuning WD, (1990) A DNA motif related to the cAMP-responsive element and an exon-located activator protein-2 binding site in the human tissue-type plasminogen activator gene promoter cooperate in basal expression and convey activation by phorbol ester and cAMP. J Biol Chem 265: 14618-14626.
32. Doetzlhofer A, Rotheneder H, Lagger G, Koranda M, Kurtev V, et al. (1999) Histone deacetylase 1 can repress transcription by binding to Sp1. Mol Cell Biol 19: 5504-5511.
33. Marinova Z, Ren M, Wendland JR, Leng Y, Liang MH, et al. (2009) Valproic acid induces functional heat-shock protein 70 via Class I histone deacetylase inhibition in cortical neurons: a potential role of Sp1 acetylation. J Neurochem 111: 976-987.
34. Huang W, Zhao S, Ammanamanchi S, Brattain M, Venkatasubbarao K, et al. (2005) Trichostatin A induces transforming growth factor beta type II receptor promoter activity and acetylation of Sp1 by recruitment of PCAF/p300 to a Sp1.NF-Y complex. J Biol Chem 280: 10047-10054.
35. Chateauvieux S, Morceau F, Dicato M, Diederich M, (2010) Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010: 1-18.
36. Hrafnkelsdottir T, Gudnason T, Wall U, Jern C, Jern S, (2004) Regulation of local availability of active tissue-type plasminogen activator in vivo in man. J Thromb Haemost 2: 1960-1968.
37. Olesen JB, Hansen PR, Abildstrom SZ, Andersson C, Weeke P, et al. (2011) Valproate attenuates the risk of myocardial infarction in patients with epilepsy: a nationwide cohort study. Pharmacoepidemiol Drug Saf 20: 146-153.